Clinical trial
A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory)
NCT04520412 is registered in ClinicalTrials.gov with Green Valley (Shanghai) Pharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory)
- Lead sponsor
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
- Phase
- Phase 3
- Overall status
- Suspended
- Start date
- October 27, 2020
- Completion date
- October 31, 2026
- Enrollment
- 2,046 (estimated)
- Sites
- 171
Conditions
As the registry lists them; a condition with its own page is linked.